4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Acrivon Therapeutics, Inc. (ACRV) operates in the Biotechnology industry and is headquartered in Watertown, United States with about 74 employees. Its market capitalization is roughly $68 million. In the fiscal year ended 2025-12-31, ACRV reported $0M in revenue and ($78M) in net income.
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($84M) | ($89M) | ($67M) | ($33M) | — |
| Net Income | ($78M) | ($81M) | ($60M) | ($31M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($20M) | ($20M) | ($20M) | ($23M) | ($22M) | — |
| Net Income | ($19M) | ($19M) | ($18M) | ($21M) | ($20M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $130M | $197M | $138M | $181M | — |
| Total Liabilities | $17M | $20M | $17M | $11M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACRV viewer.
About TickerBase · Data methodology & sources